268 related articles for article (PubMed ID: 15948002)
1. Immunogenic HER-2/neu peptides as tumor vaccines.
Baxevanis CN; Sotiriadou NN; Gritzapis AD; Sotiropoulou PA; Perez SA; Cacoullos NT; Papamichail M
Cancer Immunol Immunother; 2006 Jan; 55(1):85-95. PubMed ID: 15948002
[TBL] [Abstract][Full Text] [Related]
2. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.
Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193
[TBL] [Abstract][Full Text] [Related]
3. Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition.
Correa I; Plunkett T
Breast Cancer Res; 2001; 3(6):399-403. PubMed ID: 11737893
[TBL] [Abstract][Full Text] [Related]
4. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
5. HER-2/neu as a target for cancer vaccines.
Baxevanis CN; Voutsas IF; Gritzapis AD; Perez SA; Papamichail M
Immunotherapy; 2010 Mar; 2(2):213-26. PubMed ID: 20635929
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy.
Lekka E; Gritzapis AD; Perez SA; Tsavaris N; Missitzis I; Mamalaki A; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2010 May; 59(5):715-27. PubMed ID: 19904532
[TBL] [Abstract][Full Text] [Related]
7. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
8. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
Kobayashi H; Wood M; Song Y; Appella E; Celis E
Cancer Res; 2000 Sep; 60(18):5228-36. PubMed ID: 11016652
[TBL] [Abstract][Full Text] [Related]
9. Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy.
Baxevanis CN; Sotiropoulou PA; Sotiriadou NN; Papamichail M
Cancer Immunol Immunother; 2004 Mar; 53(3):166-75. PubMed ID: 14685781
[TBL] [Abstract][Full Text] [Related]
10. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
12. Cellular immunity to the Her-2/neu protooncogene.
Kiessling R; Wei WZ; Herrmann F; Lindencrona JA; Choudhury A; Kono K; Seliger B
Adv Cancer Res; 2002; 85():101-44. PubMed ID: 12374283
[TBL] [Abstract][Full Text] [Related]
13. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study.
Wiedermann U; Wiltschke C; Jasinska J; Kundi M; Zurbriggen R; Garner-Spitzer E; Bartsch R; Steger G; Pehamberger H; Scheiner O; Zielinski CC
Breast Cancer Res Treat; 2010 Feb; 119(3):673-83. PubMed ID: 20092022
[TBL] [Abstract][Full Text] [Related]
14. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
Ko HJ; Kim YJ; Kim YS; Chang WS; Ko SY; Chang SY; Sakaguchi S; Kang CY
Cancer Res; 2007 Aug; 67(15):7477-86. PubMed ID: 17671218
[TBL] [Abstract][Full Text] [Related]
15. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties.
Gritzapis AD; Voutsas IF; Lekka E; Tsavaris N; Missitzis I; Sotiropoulou P; Perez S; Papamichail M; Baxevanis CN
J Immunol; 2008 Jul; 181(1):146-54. PubMed ID: 18566379
[TBL] [Abstract][Full Text] [Related]
17. Vaccination against the HER-2/neu oncogenic protein.
Bernhard H; Salazar L; Schiffman K; Smorlesi A; Schmidt B; Knutson KL; Disis ML
Endocr Relat Cancer; 2002 Mar; 9(1):33-44. PubMed ID: 11914181
[TBL] [Abstract][Full Text] [Related]
18. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
Zaks TZ; Rosenberg SA
Cancer Res; 1998 Nov; 58(21):4902-8. PubMed ID: 9809997
[TBL] [Abstract][Full Text] [Related]
19. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.
Disis ML; Gooley TA; Rinn K; Davis D; Piepkorn M; Cheever MA; Knutson KL; Schiffman K
J Clin Oncol; 2002 Jun; 20(11):2624-32. PubMed ID: 12039923
[TBL] [Abstract][Full Text] [Related]
20. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
Baxevanis CN; Gritzapis AD; Tsitsilonis OE; Katsoulas HL; Papamichail M
Int J Cancer; 2002 Apr; 98(6):864-72. PubMed ID: 11948464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
